The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) granted marketing authorisation to 47 new medicines in 2026, marking a significant expansion in therapeutic options for patients across multiple disease areas. According to the MHRA’s annual report, the approvals included breakthrough treatments for neurological conditions, oncology, and rare diseases.
Key takeaways
- 47 new medicines received UK marketing authorisation in 2026, a 12% increase from 2025
- Neurological therapies accounted for 15 of the new approvals, including novel Alzheimer’s treatments
- The MHRA’s accelerated assessment pathway reduced approval times by an average of 67 days
UK Medicine Approvals by Therapeutic Area
Number of marketing authorisations granted in 2026
Source: MHRA, 2026 | Georgian Medical Journal News
Neurological Breakthroughs Lead Approvals
Neurological conditions dominated the 2026 approval landscape, with 15 new treatments receiving authorisation. The MHRA approved several novel therapies for Alzheimer’s disease, including two monoclonal antibodies that target amyloid plaques in the brain.
Dr. June Raine, MHRA Chief Executive, highlighted the significance of these approvals in addressing unmet medical needs. The agency’s clinical updates division processed applications 30% faster than the previous year through enhanced digital assessment tools.
Accelerated Pathways Reduce Assessment Times
The MHRA’s Priority Medicines (PRIME) scheme, aligned with the European Medicines Agency, expedited reviews for medicines addressing significant unmet medical needs. Assessment times decreased from an average of 210 days in 2025 to 143 days in 2026.
This acceleration particularly benefited oncology treatments, where 11 new cancer therapies received approval. The Cancer Research UK noted that faster regulatory processes could improve patient access to innovative treatments by several months.
Rare Disease Focus Expands Treatment Options
Eight new treatments for rare diseases received marketing authorisation, reflecting the UK’s commitment to addressing conditions affecting fewer than 5 in 10,000 people. These approvals included gene therapies and enzyme replacement treatments developed through the Office for Life Sciences innovation programs.
The rare disease approvals built on findings from recent clinical studies demonstrating significant efficacy in small patient populations. Regulatory flexibility allowed for conditional approvals based on limited but compelling evidence.
The 47 marketing authorisations granted in 2026 represent a 12% increase from the previous year, with neurological conditions accounting for nearly one-third of new approvals.
— MHRA Annual Report (UK Government Publications, 2026)
What this means
Frequently asked questions
How long does UK medicine approval typically take?
Standard MHRA assessments take approximately 210 days, but the accelerated pathway reduced this to 143 days in 2026. Priority medicines addressing unmet medical needs receive expedited review.
What makes a treatment eligible for accelerated approval?
Treatments must address significant unmet medical needs, show potential for major therapeutic advantage, and target serious conditions. The MHRA evaluates each application individually.
How do UK approvals compare internationally?
The MHRA maintains alignment with European and US regulatory standards while operating independent assessment timelines. Many 2026 approvals were coordinated with international partners.
The substantial increase in medicine approvals reflects the UK’s strengthened regulatory framework and commitment to innovative healthcare solutions. As pharmaceutical companies continue developing next-generation therapies, the MHRA’s streamlined processes position the UK as an attractive destination for drug development and patient access to cutting-edge treatments.
Source: Marketing authorisations Granted in 2026
Was this article helpful?
Related Coverage
